Serina Therapeutics (NYSE: SER) is an emerging small cap biopharmaceutical company developing next-generation drug optimization platform technologies with the potential to redefine standards of care across multiple therapeutic areas and drug modalities.

Serina’s patented POZ Platform offers a breakthrough in drug optimization, building on the success of PEGylation, a $150B+ drug class pioneered by their founders. POZ enables safer, more effective delivery of small molecules, RNA treatments, and ADCs by extending and controlling their release and targeting. This makes it a powerful tool for improving patient outcomes.

Their lead asset, SER-252, targets a large, underserved population living with advanced Parkinson’s disease. Backed by robust clinical validation and a potential streamlined 505(b)(2) regulatory path, SER-252 combines a best-in-class pharmacologic profile with a wearable, non-invasive delivery device. Peak sales are projected between $2.1B and $3.3B across the U.S. and Europe. This will serve as proof of principle for the POZ platform, which can then be applied to dozens of therapeutic areas leveraging the same approach: “POZylating” a clinically de-risked molecule and benefiting from accelerated cost efficient clinical/regulatory path to approval and meeting patient needs.

Watch our webinar with Serina Therapeutics CEO, Steve Ledger, to hear more about how this company’s pipeline with multiple shots on goal, wide patent moat, outlicensing and inlicensing opportunities, and several value inflection points over the next 12-18 months offer a rare opportunity to support an asset with both meaningful patient impact and significant value creation potential.